Sharemaestro company-news research for GALDERMA GROUP N (GALD), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
EBS
Switzerland
Measured evidence
Company news sentiment
GALD news sentiment
GALDERMA GROUP N
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone45Neutral is 50
Balanced news tone
42/100 evidence confidence
100% direct company focus
1 current stories across 1 publishers
Current company news
Balanced read
Balanced news tone is drawn from 1 fresh independent stories, including 1 company-specific items across 1 publishers.
Latest source headline Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping finance.yahoo.com · 11 Aug 2026 05:00What supports the read
1 current stories are mapped specifically to GALD.
What tempers the read
Only 1 publisher currently contribute to the measured read.
45/100
Weighted toneBalanced news tone
42/100
Evidence confidencebuilding confidence
100%/100
Company focus1 direct stories
N/A/100
Evidence agreementrequires at least 2 stories
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth12
1.0 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness68
recency-weighted evidenceAgreement0
requires at least 2 storiesSource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
News tone and price action are not far from neutral.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Regulatory and legal341 stories · 100%
Source mix
Where the evidence comes from
finance.yahoo.com341 stories · 100%
Recurring subjects
Subjects appearing most often
Injectable Aesthetics1Fda Approval1Dermatology1Aesthetic Treatments1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#134Tone
finance.yahoo.comDirect company coverage
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world's most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 ZUG, Switzerland, August 11, 20
Aesthetic TreatmentsDermatologyFda ApprovalInjectable Aesthetics
- Published
- 11 Aug 2026 05:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
GALD news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
05
2026
Investing.com CanadaArchivedNeutral tone
Galderma falls after FDA issues second setback for Botox rival By Investing.com
- Published
- 5 Aug 2026 04:10
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
simplywall.stArchivedNeutral tone
Evaluating Galderma Group (SWX:GALD) After Dividend Approval And Board Refresh
- Published
- 2 Aug 2026 19:27
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
10
2026
Investing.comArchivedNeutral tone
Ipsen stock falls as Galderma feud clouds strong corabotase data
- Published
- 10 Jul 2026 21:58
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
04
2026
TradingViewArchivedNeutral tone
Price to book forward of Galderma Group AG – BMV:GALD/N
- Published
- 4 Jul 2026 06:15
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
TradingViewArchivedNeutral tone
Galderma Group AG Actuals & Estimates (SIX:GALD)
- Published
- 26 Jun 2026 08:35
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.